Fibrosis-Related Biomarkers and Incident Cardiovascular Disease in Older Adults

Content Provider	Scilit
Author	Agarwal, Isha Glazer, Nicole L. Barasch, Eddy Biggs, Mary L. Djousse, Luc Fitzpatrick, Annette L. Gottdiener, John S. Ix, Joachim H. Kizer, Jorge R. Rimm, Eric B. Sicovick, David S. Tracy, Russell P. Mukamal, Kenneth J.
Copyright Year	2014
Description	Journal: Circulation: Arrhythmia and Electrophysiology Background—: Fibrotic changes in the heart and arteries have been implicated in a diverse range of cardiovascular diseases (CVD), but whether circulating biomarkers that reflect fibrosis are associated with CVD is unknown. Methods and Results—: We determined the associations of 2 biomarkers of fibrosis, transforming growth factor- β (TGF-β), and procollagen type III N-terminal propeptide (PIIINP), with incident heart failure, myocardial infarction, and stroke among community-living older adults in the Cardiovascular Health Study. We measured circulating TGF-β (n=1371) and PIIINP (n=2568) from plasma samples collected in 1996 and ascertained events through 2010. Given TGF-β’s pleiotropic effects on inflammation and fibrogenesis, we investigated potential effect modification by C-reactive protein in secondary analyses. After adjustment for sociodemographic, clinical, and biochemical risk factors, PIIINP was associated with total CVD (hazard ratio [HR] per SD=1.07; 95% confidence interval [CI], 1.01–1.14) and heart failure (HR per SD=1.08; CI, 1.01–1.16) but not myocardial infarction or stroke. TGF-β was not associated with any CVD outcomes in the full cohort but was associated with total CVD (HR per SD=1.16; CI, 1.02–1.31), heart failure (HR per SD=1.16; CI, 1.01–1.34), and stroke (HR per SD=1.20; CI, 1.01–1.42) among individuals with C-reactive protein above the median, 2.3 mg/L ( P interaction <0.05). Conclusions—: Our findings provide large-scale, prospective evidence that circulating biomarkers of fibrosis, measured in community-living individuals late in life, are associated with CVD. Further research on whether TGF-β has a stronger fibrogenic effect in the setting of inflammation is warranted.
Related Links	https://www.ahajournals.org/doi/pdf/10.1161/CIRCEP.114.001610 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140969/pdf https://www.ahajournals.org/doi/reader/10.1161/CIRCEP.114.001610
Ending Page	589
Page Count	7
Starting Page	583
ISSN	19413149
e-ISSN	19413084
DOI	10.1161/circep.114.001610
Journal	Circulation: Arrhythmia and Electrophysiology
Issue Number	4
Volume Number	7
Language	English
Publisher	Ovid Technologies (Wolters Kluwer Health)
Publisher Date	2014-08-01
Access Restriction	Open
Subject Keyword	Journal: Circulation: Arrhythmia and Electrophysiology Peripheral Vascular Disease Cardiovascular Diseases
Content Type	Text
Resource Type	Article
Subject	Physiology (medical) Cardiology and Cardiovascular Medicine